Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

154.80 +2.05 (+1.34%)
Streaming Delayed Price Updated: 10:37 AM EDT, Apr 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
43 44 Next >
News headline image
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch ↗
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed. 
Via Benzinga
News headline image
Could This Be Novartis' Next Blockbuster Medicine? ↗
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug. 
Via The Motley Fool
Hopeful Golden Cross Forms On Novartis's Chart ↗
 
Via Benzinga
5 Value Stocks In The Healthcare Sector ↗
 
Via Benzinga
A Bullish Sign Appears On Novartis's Chart ↗
 
Via Benzinga
News headline image
Novartis' Rare Blood Disorder Therapy Aces Second Late-Stage Trial ↗
 
Via Benzinga
News headline image
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering ↗
 
Via Benzinga
News headline image
3 Drug Stocks With Promising Pipelines for 2023 ↗
These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors. 
Via InvestorPlace
News headline image
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects ↗
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem. 
Via Benzinga
News headline image
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide ↗
Cantor Fitzgerald published around 40-page deep dive ahead of Novo Nordisk A/S's (NYSE: NVO) SELECT CV outcomes study, which is guided to complete in ~mid-2023.  
Via Benzinga
News headline image
Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalmology, Respiratory Units ↗
Novartis AG (NYSE: NVS) said it would narrow its focus on five core therapeutic areas, including cardiovascular, immunology, neurodegenerative diseases, solid tumors, and hematology. 
Via Benzinga
News headline image
3 Biotech Companies to Watch in 2023 ↗
These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year. 
Via InvestorPlace
News headline image
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
News headline image
2 Top Biotech Stocks to Buy Right Now ↗
These two pharmaceutical companies pay market-beating dividends to shareholders. 
Via The Motley Fool
News headline image
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca ↗
GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.' 
Via Benzinga
News headline image
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond ↗
These two biotechs are flying high right now. 
Via The Motley Fool
News headline image
Elon Musk Tells Employees Tesla Will Be 'Most Valuable Company On Earth, Sam Bankman-Fried Set To Enter Plea On Fraud Case, Twitter 'Should Feel Faster': Today's Top Stories ↗
Reuters 
Via Benzinga
News headline image
Novartis Settles Antitrust Cases Related To Generic Entry For Hypertension Drug ↗
Novartis AG (NYSE: NVS) will pay $245 million to end antitrust litigation accusing the company of trying to delay the U.S. launch of generic versions of its Exforge, which treats hypertension to lower... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
3 Ridiculously Cheap Dividend Stocks That Yield More Than 3% ↗
You're getting a lot of bang for your buck with these stocks. 
Via The Motley Fool
News headline image
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says ↗
 
Via Benzinga
News headline image
Pfizer, Novartis Are Among Overbought Healthcare Stocks: Are They Worth A Look? ↗
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. Here’s the latest list of major overbought players in this sector, with an RSI... 
Via Benzinga
News headline image
A Career Politician Who Regularly Trades The SPY, Picked Up There 3 High Yielding ETFs Instead ↗
Representative Robert Wittman (R-VA) is the vice-ranking member of the House Armed Services Committee and also serves on the Committee on Natural Resources. 
Via Benzinga
News headline image
Novartis Shares Detailed Results From Experimental Drug For Rare Blood Disorder ↗
 
Via Benzinga
News headline image
Why Merck's $250 Million Investment In Moderna May Have Just Paid Off ↗
Merck opted into Moderna's cancer vaccine. Now, the companies have Phase 2 data. 
Via Investor's Business Daily
News headline image
CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy ↗
Clovis Oncology (CLVS) stock is on the move Monday as investors react to the pharmaceutical company filing for bankruptcy protection. 
Via InvestorPlace
News headline image
Erasca Oulicenses Its Mid-Stage Cancer Program To Novartis, Raises $100M Via Equity Offering ↗
 
Via Benzinga
News headline image
3 Hot Stocks That Could Live Up to Their Lofty Valuations ↗
These companies have long runways of growth ahead 
Via The Motley Fool
News headline image
MorphoSys Inks Licensing Agreement With Novartis For Preclinical Cancer Programs ↗
 
Via Benzinga
News headline image
Novartis' Kisqali Prolongs Progression Free Survival Benefit In Metastatic Breast Cancer Versus Chemo ↗
 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
43 44 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.